Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NRIX
7. SPY
8. SUNS
9. NVDA
10. OIG

Go back to Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD)

MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results

November 6, 2019 8:01 AM EST

3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018°  3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018      Afrezza sold to our marketing partner in Brazil for launch was $0.7 million°  3Q 2019 Collaborations and Services Revenue was $8.2 million Debt financing completed providing up to $75.0 million in non-dilutive capital Received second $12.5 million milestone payment from United Therapeutics in November 2019Advanced Technosphere® formulations of sumatriptan and tadalafil into nonclinical pharmacology studies... More